Researchers report the ability to improve safety and efficacy using a CRISPR-Cas9 variant known as miCas9.
Using a new variant to repair DNA will improve both safety and effectiveness of the much-touted CRISPR-Cas9 tool in genetic research, Michigan Medicine researchers say.
Those two key problems – safety and efficacy – are what continue to hold CRISPR-Cas9 gene targeting back from its full clinical potential, explains co-senior author Y. Eugene Chen, M.D., Ph.D., a professor of internal medicine, cardiac surgery, physiology, pharmacology and medicinal chemistry, from the Michigan Medicine Frankel Cardiovascular Center.
The new CRISPR-Cas9 variant improves efficiency when inserting a gene or DNA fragment to a precise location in the genome, known as knocking in. It also reduces the rate of unintended insertions or deletions, known as indels, of base pairs that often happen while gene editing.
“We name it meticulous integration Cas9, or miCas9, to reflect its extraordinary capacity to enable maximum integration, yet with minimal indels, as well as to recognize its development at the University of Michigan,” write senior authors Chen, Jifeng Zhang and Jie Xu for Nature’s “Behind the Paper” series. “It provides a ‘one small stone for three birds’ tool in gene editing.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
MiCas9
- Feed has no items.
Go deeper with Google Headlines on:
MiCas9
[google_news title=”” keyword=”miCas9″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
CRISPR-Cas9
- New Zealand: How gene technology is changing future of food
Opinion: Ethical use of genetic tech may accelerate the adoption of new crops and animals.
- Buy Rating on Crispr Therapeutics AG Backed by Exa-cel’s Precision and Favorable Safety Profile
Salim Syed, an analyst from Mizuho Securities, maintained the Buy rating on Crispr Therapeutics AG (CRSP – Research Report). The ...
- This AI Just Designed a More Precise CRISPR Gene Editor for Human Cells From Scratch
Based on large language models—the tech behind the popular ChatGPT—Profluent's AI designed a new gene editor and put it to work in human cells.
- Peninsula biotech co-founded by Jennifer Doudna lands CRISPR gene-editing pact with Regeneron
The big deal between Regeneron and a Peninsula biotech co-founded by Jennifer Doudna is also a small deal. And that’s a huge deal.
- Regeneron and Mammoth strike $100M deal to pair tiny CRISPR editors with new delivery idea
Regeneron is expanding its genetic medicine efforts and will work with California startup Mammoth Biosciences on gene-editing programs reaching parts of the human body beyond the liver, the companies ...
Go deeper with Google Headlines on:
CRISPR-Cas9
[google_news title=”” keyword=”CRISPR-Cas9″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
